In June 2022, the Munich-based startup Kranus Health closed its Series A round with 6.1 million euros (6.5 million dollars). Now the company announced an expansion of its Series A to a total of €14.3 million ($15 million). New investor SwissHealth Ventures led the financing round together with existing investor Karista. All other existing investors (HTGF, Wenvest, and A Round Capital) also participated again.
Kranus Health plans to use the fresh capital to expand into additional markets outside of Germany. In June, the startup expanded its presence in France by opening its third office in Paris. Jens Nörtershäuser, Co-Founder and Co-CEO of Kranus Health, says:
"We are convinced that now is the right time for the global dissemination of digital healthcare models. The EU is a pioneer in integrated healthcare offerings, which are also becoming increasingly popular internationally."
Kranus Health revolutionizes urological care
With the new investor SwissHealth Ventures, the Swiss health insurer CSS is creating the necessary structures to invest in innovative startups in the healthcare sector. Philomena Colatrella, CEO of CSS, on the reason for the partnership:
“Our belief in Kranus Health’s groundbreaking approach to integrated urological care aligns perfectly with our mission to drive transformative change in healthcare and improve its accessibility and effectiveness for all.”
Kranus Health's mission is to revolutionize urology with technological innovations. The primary goal is to facilitate access to effective therapies for urological diseases. The company is therefore developing digital solutions for the treatment of a wide range of urological diseases.
With Kranus Edera, the company has already launched the first digital health application as a fully reimbursable "prescription app" for the treatment of erectile dysfunction and its causes. The results of a related study at Münster University Hospital indicate an improvement in erectile dysfunction and quality of life. Another product, Kranus Lutera, is also expected to be reimbursable early next year and closes a gap in the treatment of benign prostatic hyperplasia (BPH). Further urological therapies for men and women are currently being planned.
